No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PHAT Phathom Pharmaceuticals
- 10.945
- -0.235-2.10%
Close Jul 19 16:00 ET
640.67MMarket Cap-2454P/E (TTM)
12.060High10.760Low1.11MVolume11.290Open11.180Pre Close12.49MTurnover2.41%Turnover RatioLossP/E (Static)58.54MShares17.01952wk High-4.31P/B502.31MFloat Cap6.06552wk Low--Dividend TTM45.89MShs Float64.540Historical High--Div YieldTTM11.63%Amplitude5.840Historical Low11.300Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Matthew Caufield maintains $Phathom Pharmaceuticals(PHAT.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Terveystalo Oy (OtherTTALF)
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $26 to $28
On Jul 19, major Wall Street analysts update their ratings for $Phathom Pharmaceuticals(PHAT.US)$, with price targets ranging from $26 to $28.Goldman Sachs analyst Paul Choi maintains with a hold
Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna's NERD Indication Approval and Robust Sales Forecast
Don't Ignore The Insider Selling In Phathom Pharmaceuticals
Anyone interested in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) should probably be aware that the President, Terrie Curran, recently divested US$397k worth of shares in the company, at an average
Comments
$Phathom Pharmaceuticals(PHAT.US$ In a report released today, from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
$Phathom Pharmaceuticals(PHAT.US$ FDA Approves VOQUEZNA® for Relief of Heartburn
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
3
$Phathom Pharmaceuticals(PHAT.US$ Phathom Pharmaceuticals Announces FDA Approval of Voquezna® (Vonoprazan) Tablets for the Relief of Heartburn Associated With Non-Erosive Gerd in Adults
1
Don't miss out! 🎯👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg